|CAS Number||124378-77-4 Y|
|Chemical and physical data|
|Molar mass||396.52 g/mol|
|3D model (Jmol)||Interactive image|
It was studied as a potential analgesic, but abandoned because of the dose-limiting effects of dysphoria, which could be expected from a κ-opioid agonist. There was mention of its potential in treating comatose head injury or stroke victims, where that type of side effect would be immaterial.
When enadoline was first reported in 1990, it was "the most potent κ-selective analgesic ever reported ... 25 times more potent than morphine and 17 times more potent than U-62066".
- Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001). "Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans". Psychopharmacology (Berl.). 157 (2): 151–62. doi:10.1007/s002130100788. PMID 11594439.
- Barber A, Gottschlich R (1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opin Investig Drugs. 6 (10): 1351–68. doi:10.1517/135437184.108.40.2061. PMID 15989506.
- Halfpenny, Paul R.; Horwell, David C.; Hughes, John; Hunter, John C.; Rees, David C. (1990). "Highly selective .kappa.-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted cyclohexyl]arylacetamide derivatives". Journal of Medicinal Chemistry. 33 (1): 286–91. doi:10.1021/jm00163a047. PMID 2153208.
See also: Peptide receptor modulators